Literature DB >> 20532952

Macular vitelliform lesion in desferrioxamine-related retinopathy.

Mohamed A Genead1, Gerald A Fishman, Anastasios Anastasakis, Martin Lindeman.   

Abstract

To report a case of a macular vitelliform lesion associated with desferrioxamine treatment. Ocular, electrophysiological, psychophysical, perimetric, fluorescein angiographic, fundus autofluorescence, and spectral-domain OCT examinations were obtained on a 45-year-old Caucasian woman with thalassemia major treated with blood transfusions and desferrioxamine. The patient was observed to have a vitelliform macular lesion in the right eye with a hypopigmented macular lesion and retinal pigment mottling in the left. At the most recent follow-up visit, best-corrected visual acuity was 20/70 in the right eye and 20/25 in left. Full-field electroretinogram (ERG) testing showed normal cone and rod responses. Mild localized elevations of rod psychophysical thresholds were found. A vitelliform macular lesion can develop in patients treated with desferrioxamine. Some such patients may not show diffuse photoreceptor cell functional loss as determined by electrophysiological testing.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20532952      PMCID: PMC3690284          DOI: 10.1007/s10633-010-9236-z

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN: 0012-4486            Impact factor:   2.379


  18 in total

1.  Bull's eye maculopathy with deferoxamine.

Authors:  V Bansal; I Elgarbly; F D Ghanchi; P L Atkinson
Journal:  Eur J Haematol       Date:  2003-06       Impact factor: 2.997

2.  Bilateral vitelliform maculopathy and deferoxamine toxicity.

Authors:  Christine R Gonzales; Albert P Lin; Robert E Engstrom; Allan E Kreiger
Journal:  Retina       Date:  2004-06       Impact factor: 4.256

3.  Standard for clinical electroretinography (2004 update).

Authors:  Michael F Marmor; Graham E Holder; Mathias W Seeliger; Shuichi Yamamoto
Journal:  Doc Ophthalmol       Date:  2004-03       Impact factor: 2.379

4.  Ocular changes in patients undergoing long-term desferrioxamine treatment.

Authors:  G B Arden; B Wonke; C Kennedy; E R Huehns
Journal:  Br J Ophthalmol       Date:  1984-12       Impact factor: 4.638

5.  The expanded clinical spectrum of deferoxamine retinopathy.

Authors:  Robert Haimovici; Donald J D'Amico; Evangelos S Gragoudas; Samuel Sokol
Journal:  Ophthalmology       Date:  2002-01       Impact factor: 12.079

6.  Ocular and auditory toxicity of long-term, high-dose subcutaneous deferoxamine therapy.

Authors:  R B Orton; L L de Veber; H M Sulh
Journal:  Can J Ophthalmol       Date:  1985-06       Impact factor: 1.882

7.  Deferoxamine (Desferal)-induced toxic retinal pigmentary degeneration and presumed optic neuropathy.

Authors:  V Lakhanpal; S S Schocket; R Jiji
Journal:  Ophthalmology       Date:  1984-05       Impact factor: 12.079

8.  Ocular toxicity of high-dose intravenous desferrioxamine.

Authors:  S C Davies; R E Marcus; J L Hungerford; M H Miller; G B Arden; E R Huehns
Journal:  Lancet       Date:  1983-07-23       Impact factor: 79.321

Review 9.  Iron chelators for the treatment of iron overload disease: relationship between structure, redox activity, and toxicity.

Authors:  Timothy B Chaston; Des R Richardson
Journal:  Am J Hematol       Date:  2003-07       Impact factor: 10.047

View more
  11 in total

1.  Electrophysiological assessment for early detection of retinal dysfunction in β-thalassemia major patients.

Authors:  Maria Dettoraki; Antonis Kattamis; Ioannis Ladas; Konstantinos Maragkos; Chryssanthi Koutsandrea; Klio Chatzistefanou; Konstantinos Laios; Dimitrios Brouzas; Marilita M Moschos
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-03-30       Impact factor: 3.117

Review 2.  Ocular abnormalities in beta thalassemia patients: prevalence, impact, and management strategies.

Authors:  Samira Heydarian; Reza Jafari; Kiumars Nowroozpoor Dailami; Hassan Hashemi; Ebrahim Jafarzadehpour; Mohsen Heirani; Abbasali Yekta; Monireh Mahjoob; Mehdi Khabazkhoob
Journal:  Int Ophthalmol       Date:  2019-10-10       Impact factor: 2.031

3.  Pseudovitelliform maculopathy associated with deferoxamine toxicity: multimodal imaging and electrophysiology of a rare entity.

Authors:  Kelly M Bui; SriniVas R Sadda; Hani Salehi-Had
Journal:  Digit J Ophthalmol       Date:  2017-02-13

4.  Efficacy of brinzolamide ophthalmic suspension 1% for treatment of a vitelliform macular lesion in a patient with desferrioxamine retinopathy.

Authors:  Mohamed A Genead; Gerald A Fishman
Journal:  Ophthalmic Surg Lasers Imaging       Date:  2011-12-08

5.  Multimodal imaging in a case of deferoxamine-induced maculopathy.

Authors:  Rony Gelman; Szilard Kiss; Stephen H Tsang
Journal:  Retin Cases Brief Rep       Date:  2014

Review 6.  Retinal abnormalities in β-thalassemia major.

Authors:  Devang L Bhoiwala; Joshua L Dunaief
Journal:  Surv Ophthalmol       Date:  2015-08-29       Impact factor: 6.048

Review 7.  Functional and Structural Abnormalities in Deferoxamine Retinopathy: A Review of the Literature.

Authors:  Maura Di Nicola; Giulio Barteselli; Laura Dell'Arti; Roberto Ratiglia; Francesco Viola
Journal:  Biomed Res Int       Date:  2015-06-08       Impact factor: 3.411

Review 8.  β-Thalassemia and ocular implications: a systematic review.

Authors:  Aliki Liaska; Petros Petrou; Constantinos D Georgakopoulos; Ramza Diamanti; Dimitris Papaconstantinou; Menelaos G Kanakis; Ilias Georgalas
Journal:  BMC Ophthalmol       Date:  2016-07-08       Impact factor: 2.209

Review 9.  Clinical applications of fundus autofluorescence in retinal disease.

Authors:  Madeline Yung; Michael A Klufas; David Sarraf
Journal:  Int J Retina Vitreous       Date:  2016-04-08

10.  Pattern dystrophies in patients treated with deferoxamine: report of two cases and review of the literature.

Authors:  Constantine D Georgakopoulos; Foteini Tsapardoni; Elli V Kostopoulou; Olga E Makri
Journal:  BMC Ophthalmol       Date:  2018-09-12       Impact factor: 2.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.